|
TWI229650B
(en)
*
|
2002-11-19 |
2005-03-21 |
Sharp Kk |
Substrate accommodating tray
|
|
US9745103B2
(en)
|
2006-05-05 |
2017-08-29 |
Illinois Tool Works Inc. |
Wide mouth gusseted pouches
|
|
PL2059533T3
(pl)
|
2006-08-30 |
2013-04-30 |
Genentech Inc |
Przeciwciała wieloswoiste
|
|
BRPI0717431A2
(pt)
|
2006-09-29 |
2013-11-12 |
Oncomed Pharm Inc |
Composições e métodos de diagnóstico e tratamento do câncer
|
|
AU2008282218A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
KR102467302B1
(ko)
|
2007-09-26 |
2022-11-14 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
CN102014913A
(zh)
*
|
2008-03-06 |
2011-04-13 |
健泰科生物技术公司 |
C-met和egfr拮抗剂的联合疗法
|
|
CN112481367A
(zh)
*
|
2008-03-31 |
2021-03-12 |
健泰科生物技术公司 |
用于治疗和诊断哮喘的组合物和方法
|
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
US8193321B2
(en)
*
|
2008-09-03 |
2012-06-05 |
Genentech, Inc. |
Multispecific antibodies
|
|
MA33198B1
(fr)
|
2009-03-20 |
2012-04-02 |
Genentech Inc |
Anticorps anti-her di-spécifiques
|
|
RU2011142974A
(ru)
|
2009-03-25 |
2013-04-27 |
Дженентек, Инк. |
НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
|
|
ES2708124T3
(es)
|
2009-04-27 |
2019-04-08 |
Oncomed Pharm Inc |
Procedimiento para preparar moléculas heteromultiméricas
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
ES2895226T3
(es)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
|
|
ES2594893T3
(es)
|
2009-12-16 |
2016-12-23 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti HER2 y sus usos
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
US8846041B2
(en)
|
2010-03-24 |
2014-09-30 |
Genentech, Inc. |
Anti-LRP6 antibodies
|
|
CA2794483C
(en)
|
2010-03-26 |
2020-07-07 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
JP5940061B2
(ja)
|
2010-06-18 |
2016-06-29 |
ジェネンテック， インコーポレイテッド |
抗ａｘｌ抗体及び使用方法
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
CA2803792A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
|
CA2805709A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
|
CA2805564A1
(en)
|
2010-08-05 |
2012-02-09 |
Stefan Jenewein |
Anti-mhc antibody anti-viral cytokine fusion protein
|
|
CA2806640A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
|
NO2603530T3
(pl)
|
2010-08-13 |
2018-04-07 |
|
|
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
|
RU2013114360A
(ru)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
Биомаркеры и способы лечения
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
TW201300417A
(zh)
|
2010-11-10 |
2013-01-01 |
Genentech Inc |
用於神經疾病免疫療法之方法及組合物
|
|
US20120134924A1
(en)
*
|
2010-11-30 |
2012-05-31 |
Magnetus, Llc |
Micro-Vesicles Providing Contrast To Target Tissue Electrical Property Gradients
|
|
EP3208282A1
(en)
|
2010-11-30 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
|
|
KR101615474B1
(ko)
|
2010-12-16 |
2016-04-25 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
|
MA34881B1
(fr)
|
2010-12-20 |
2014-02-01 |
Genentech Inc |
Anticorps et immunoconjugués anti-mésothéline
|
|
MA34818B1
(fr)
|
2010-12-22 |
2014-01-02 |
Genentech Inc |
Anticorps anti-pcsk9 et procédés d'utilisation
|
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
CN103502271B
(zh)
|
2011-02-28 |
2016-10-26 |
霍夫曼-拉罗奇有限公司 |
抗原结合蛋白
|
|
ES2692268T3
(es)
|
2011-03-29 |
2018-12-03 |
Roche Glycart Ag |
Variantes de Fc de anticuerpo
|
|
CN103596983B
(zh)
|
2011-04-07 |
2016-10-26 |
霍夫曼-拉罗奇有限公司 |
抗fgfr4抗体及使用方法
|
|
AU2012244816B2
(en)
|
2011-04-20 |
2015-12-10 |
Roche Glycart Ag |
Method and constructs for the pH dependent passage of the blood-brain-barrier
|
|
JP5987053B2
(ja)
|
2011-05-12 |
2016-09-06 |
ジェネンテック， インコーポレイテッド |
フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
|
|
BR112013026266A2
(pt)
|
2011-05-16 |
2020-11-10 |
Genentech, Inc |
método de tratamento, anticorpos isolado e anti-fgfr1, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de diabetes em um indivíduo
|
|
WO2012163521A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Removal of monomeric targets
|
|
FI2726510T3
(fi)
*
|
2011-05-27 |
2023-05-04 |
Hoffmann La Roche |
Kaksoiskohdennus
|
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
|
SG194932A1
(en)
|
2011-06-30 |
2013-12-30 |
Genentech Inc |
Anti-c-met antibody formulations
|
|
MX2014001766A
(es)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Anticuerpos de neuregulina y sus usos.
|
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
MX2014002436A
(es)
|
2011-08-31 |
2014-05-27 |
Genentech Inc |
Marcadores de diagnostico.
|
|
RU2014109395A
(ru)
|
2011-09-15 |
2015-10-20 |
Дженентек, Инк. |
Способы стимуляции дифференциации
|
|
BR112014006419A2
(pt)
|
2011-09-19 |
2018-08-07 |
Genentech Inc |
métodos para tratar um paciente com câncer, kit e artigo
|
|
PL3485903T3
(pl)
|
2011-09-23 |
2023-06-12 |
Mereo Biopharma 5, Inc. |
Środki wiążące VEGF/DLL4 i ich zastosowania
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
|
EP3461839A1
(en)
|
2011-10-14 |
2019-04-03 |
F. Hoffmann-La Roche AG |
Anti-htra1 antibodies and methods of use
|
|
JP6254087B2
(ja)
|
2011-10-15 |
2017-12-27 |
ジェネンテック， インコーポレイテッド |
癌を治療するためのｓｃｄ１アンタゴニスト
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
CN104039340B
(zh)
|
2011-10-28 |
2017-04-05 |
霍夫曼-拉罗奇有限公司 |
治疗黑素瘤的方法及治疗剂组合
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
|
EP2602265A1
(en)
*
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antibodies anti-sPLA2-X and uses thereof
|
|
MX355624B
(es)
|
2011-12-22 |
2018-04-25 |
Hoffmann La Roche |
Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
|
|
ES2791758T3
(es)
|
2011-12-22 |
2020-11-05 |
Hoffmann La Roche |
Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos
|
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
|
WO2013120929A1
(en)
|
2012-02-15 |
2013-08-22 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
|
CN102633883B
(zh)
*
|
2012-02-24 |
2014-06-25 |
上海白泽生物科技有限公司 |
一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
|
|
CN104220457A
(zh)
|
2012-03-27 |
2014-12-17 |
霍夫曼-拉罗奇有限公司 |
涉及her3抑制剂的诊断和治疗
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
CN114163530A
(zh)
|
2012-04-20 |
2022-03-11 |
美勒斯公司 |
用于产生免疫球蛋白样分子的方法和手段
|
|
RU2014148162A
(ru)
|
2012-05-01 |
2016-06-20 |
Дженентек, Инк. |
Анти-pmel17 антитела и их иммуноконъюгаты
|
|
CN104583239B
(zh)
|
2012-05-10 |
2018-09-18 |
生物蛋白有限公司 |
多特异单克隆抗体
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
KR102115438B1
(ko)
|
2012-05-21 |
2020-05-27 |
제넨테크, 인크. |
혈액-뇌 장벽 수송의 안전성을 개선하는 방법
|
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
|
RU2014149681A
(ru)
*
|
2012-05-24 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитела с множественной специфичностью
|
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
JP6247287B2
(ja)
|
2012-07-04 |
2017-12-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ビオチン抗体および使用方法
|
|
CN107082810B
(zh)
|
2012-07-04 |
2020-12-25 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
|
KR102090849B1
(ko)
|
2012-07-04 |
2020-03-19 |
에프. 호프만-라 로슈 아게 |
공유 결합된 항원-항체 접합체
|
|
CA2877009C
(en)
|
2012-07-05 |
2023-10-03 |
Devin TESAR |
Expression and secretion system
|
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
|
AR091700A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b
|
|
EP2869849A1
(en)
|
2012-07-09 |
2015-05-13 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
|
JP6297550B2
(ja)
|
2012-07-09 |
2018-03-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ７９ｂ抗体を含む免疫複合体
|
|
EP3495387B1
(en)
|
2012-07-13 |
2021-09-01 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
EP2875356A1
(en)
*
|
2012-07-23 |
2015-05-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method for diagnosing scleroderma
|
|
PL2900694T3
(pl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Dwuswoiste przeciwciała igg jako aktywatory komórek t
|
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
|
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
|
US20150259430A1
(en)
|
2012-11-05 |
2015-09-17 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
CN104968367B
(zh)
|
2012-11-13 |
2018-04-13 |
弗·哈夫曼-拉罗切有限公司 |
抗血凝素抗体和使用方法
|
|
WO2014086496A1
(en)
*
|
2012-12-05 |
2014-06-12 |
Dutalys Gmbh |
Dual targeting
|
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
|
EP2964260A2
(en)
|
2013-03-06 |
2016-01-13 |
F. Hoffmann-La Roche AG |
Methods of treating and preventing cancer drug resistance
|
|
WO2014159835A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
JP2016515132A
(ja)
|
2013-03-14 |
2016-05-26 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
EP2970476A1
(en)
|
2013-03-15 |
2016-01-20 |
F. Hoffmann-La Roche AG |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
JP2016520528A
(ja)
|
2013-03-15 |
2016-07-14 |
ジェネンテック， インコーポレイテッド |
癌の治療及び抗癌剤耐性の防止方法
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
EP3878866A1
(en)
|
2013-04-29 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
WO2014177460A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3046940B1
(en)
|
2013-09-17 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Methods of using anti-lgr5 antibodies
|
|
BR112016007635A2
(pt)
|
2013-10-11 |
2017-09-12 |
Genentech Inc |
inibidores de nsp4 e métodos de uso
|
|
JP6422956B2
(ja)
|
2013-10-11 |
2018-11-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性ドメイン交換共通可変軽鎖抗体
|
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
|
CA2924873A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
|
EP3783020A1
(en)
|
2013-11-21 |
2021-02-24 |
F. Hoffmann-La Roche AG |
Anti-alpha-synuclein antibodies and methods of use
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
JP7325166B2
(ja)
*
|
2013-12-20 |
2023-08-14 |
ジェネンテック， インコーポレイテッド |
二重特異性抗体
|
|
CR20160270A
(es)
|
2013-12-20 |
2016-09-05 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
JP6590810B2
(ja)
|
2013-12-24 |
2019-10-16 |
ヤンセン ファーマシューティカ エヌブイ |
抗ｖｉｓｔａ抗体および断片
|
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
|
CN111057147B
(zh)
|
2014-01-06 |
2023-11-10 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
|
KR20160107190A
(ko)
|
2014-01-15 |
2016-09-13 |
에프. 호프만-라 로슈 아게 |
변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
AU2015209154A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-STEAP1 antibodies and immunoconjugates
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
TW202239429A
(zh)
|
2014-02-08 |
2022-10-16 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
TWI705824B
(zh)
|
2014-02-08 |
2020-10-01 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
ES2685424T3
(es)
|
2014-02-12 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-Jagged1 y procedimientos de uso
|
|
MX2016010729A
(es)
|
2014-02-21 |
2016-10-26 |
Genentech Inc |
Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
|
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
|
CR20160425A
(es)
|
2014-03-14 |
2017-05-26 |
Novartis Ag |
Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
CN107002119A
(zh)
|
2014-03-24 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
|
|
SG11201608106PA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
PE20211291A1
(es)
|
2014-03-31 |
2021-07-20 |
Genentech Inc |
Anticuerpos anti-ox40 y metodos de uso
|
|
EP3126389A1
(en)
|
2014-04-02 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Method for detecting multispecific antibody light chain mispairing
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
|
NZ726514A
(en)
|
2014-05-29 |
2019-01-25 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
|
CN106459202A
(zh)
|
2014-06-11 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
抗LgR5抗体及其用途
|
|
WO2015191881A2
(en)
|
2014-06-11 |
2015-12-17 |
Green Kathy A |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
EP3164419A1
(en)
|
2014-06-26 |
2017-05-10 |
F. Hoffmann-La Roche AG |
Anti-brdu antibodies and methods of use
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
CN106574270B
(zh)
|
2014-07-03 |
2021-07-13 |
豪夫迈·罗氏有限公司 |
多肽表达系统
|
|
NZ728041A
(en)
|
2014-07-10 |
2023-01-27 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington’s disease
|
|
DK3309174T3
(da)
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
|
|
EP3166627A1
(en)
|
2014-07-11 |
2017-05-17 |
Genentech, Inc. |
Notch pathway inhibition
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
MX2017003022A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados.
|
|
CN107108724A
(zh)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
半胱氨酸改造抗体和缀合物
|
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗－ｂ７－ｈ４抗體及免疫結合物
|
|
MX2017003126A
(es)
|
2014-09-12 |
2017-08-28 |
Genentech Inc |
Anticuerpos anti-her2 e inmunoconjugados.
|
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EP3197917B1
(en)
|
2014-09-26 |
2022-10-12 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
|
|
ES2952717T3
(es)
|
2014-10-14 |
2023-11-03 |
Novartis Ag |
Moléculas de anticuerpos contra PD-L1 y usos de las mismas
|
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
|
CN107530419B
(zh)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
治疗疾病的组合疗法
|
|
RU2017119009A
(ru)
|
2014-11-03 |
2018-12-05 |
Дженентек, Инк. |
Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
|
|
RU2017119231A
(ru)
|
2014-11-03 |
2018-12-06 |
Дженентек, Инк. |
Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
WO2016071377A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
TWI705976B
(zh)
|
2014-11-10 |
2020-10-01 |
美商建南德克公司 |
抗介白素-33抗體及其用途
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
WO2016081639A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
JP6802158B2
(ja)
|
2014-12-05 |
2020-12-16 |
ジェネンテック， インコーポレイテッド |
抗ＣＤ７９ｂ抗体及び使用方法
|
|
CA2969730A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
AU2015360579A1
(en)
|
2014-12-10 |
2017-05-18 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
BR112017011170A2
(pt)
|
2014-12-18 |
2018-02-27 |
Hoffmann La Roche |
método para determinar a citotoxicidade dependente do complemento de uma composição
|
|
ES2899894T3
(es)
|
2014-12-19 |
2022-03-15 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-C5 y métodos de uso
|
|
JP2018503399A
(ja)
*
|
2015-01-14 |
2018-02-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
多特異性免疫調節抗原結合構築物
|
|
CN107428823B
(zh)
|
2015-01-22 |
2021-10-26 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
|
JP6602875B2
(ja)
|
2015-01-26 |
2019-11-06 |
マクロジェニクス，インコーポレーテッド |
Ｄｒ５結合ドメインを含む多価分子
|
|
EA201791754A1
(ru)
|
2015-02-05 |
2019-01-31 |
Чугаи Сейяку Кабусики Кайся |
АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
|
|
SI3265557T1
(sl)
|
2015-03-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Ultraprečiščena DsbA in DsbC ter postopki njune izdelave in uporabe
|
|
KR20170127011A
(ko)
|
2015-03-16 |
2017-11-20 |
제넨테크, 인크. |
Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
MX2017012802A
(es)
|
2015-04-07 |
2018-04-11 |
Alector Llc |
Anticuerpos antisortilina y métodos para su uso.
|
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
|
KR20170134642A
(ko)
|
2015-04-08 |
2017-12-06 |
노파르티스 아게 |
Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
|
|
UA126272C2
(uk)
|
2015-06-05 |
2022-09-14 |
Дженентек, Інк. |
Антитіло проти тау-білка та спосіб його застосування
|
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
WO2016205176A1
(en)
|
2015-06-15 |
2016-12-22 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
|
CN113929779A
(zh)
|
2015-06-24 |
2022-01-14 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
|
JP6782716B2
(ja)
|
2015-06-25 |
2020-11-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体またはリガンドの結合および機能を明らかにするための細胞ベースアッセイ法
|
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
AU2016288461B2
(en)
|
2015-06-29 |
2021-10-07 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
CA2991880A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
HUE056201T2
(hu)
|
2015-07-30 |
2022-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
EP3350202A1
(en)
|
2015-09-18 |
2018-07-25 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
ES2968074T3
(es)
|
2015-09-23 |
2024-05-07 |
Mereo Biopharma 5 Inc |
Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
|
|
WO2017053807A2
(en)
|
2015-09-23 |
2017-03-30 |
Genentech, Inc. |
Optimized variants of anti-vegf antibodies
|
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
ES2895034T3
(es)
|
2015-10-02 |
2022-02-17 |
Hoffmann La Roche |
Anticuerpos anti-PD1 y procedimientos de uso
|
|
MX2018004177A
(es)
|
2015-10-08 |
2018-09-11 |
Macrogenics Inc |
Terapia de combinacion para el tratamiento de cancer.
|
|
CN115925944A
(zh)
|
2015-10-23 |
2023-04-07 |
美勒斯公司 |
抑制癌症生长的结合分子
|
|
MX2018005036A
(es)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
MA43113B1
(fr)
|
2015-10-30 |
2021-06-30 |
Hoffmann La Roche |
Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
RU2742606C2
(ru)
|
2015-12-18 |
2021-02-09 |
Чугаи Сейяку Кабусики Кайся |
Антитела к с5 и способы их применения
|
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
US20170233472A1
(en)
|
2016-02-17 |
2017-08-17 |
Macrogenics, Inc. |
ROR1-Binding Molecules, and Methods of Use Thereof
|
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
CA3016563A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
EP3433621A1
(en)
|
2016-03-25 |
2019-01-30 |
H. Hoffnabb-La Roche Ag |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
|
MX2018012418A
(es)
|
2016-04-15 |
2019-07-10 |
Bioatla Llc |
Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
|
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
|
BR112018069890A2
(pt)
|
2016-05-02 |
2019-02-05 |
Hoffmann La Roche |
polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
JP7051715B2
(ja)
|
2016-05-13 |
2022-04-11 |
バイオアトラ、エルエルシー |
抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
|
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
WO2017218977A2
(en)
|
2016-06-17 |
2017-12-21 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック， インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
|
RU2019105693A
(ru)
|
2016-08-01 |
2020-09-01 |
Новартис Аг |
Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
|
|
US11649285B2
(en)
|
2016-08-03 |
2023-05-16 |
Bio-Techne Corporation |
Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
JP7125347B2
(ja)
|
2016-08-22 |
2022-08-24 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
|
EA201990578A1
(ru)
|
2016-09-23 |
2019-10-31 |
|
Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
|
|
UA124269C2
(uk)
|
2016-09-23 |
2021-08-18 |
Дженентек, Інк. |
Застосування антагоністу il-13 для лікування атопічного дерматиту
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
|
AU2017361081A1
(en)
|
2016-11-15 |
2019-05-23 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
WO2018106781A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc |
Anti-tau antibodies and methods of use
|
|
EP3551655A2
(en)
|
2016-12-07 |
2019-10-16 |
Genentech, Inc. |
Anti-tau antibodies and methods of their use
|
|
WO2018108759A1
(en)
|
2016-12-13 |
2018-06-21 |
F. Hoffmann-La Roche Ag |
Method to determine the presence of a target antigen in a tumor sample
|
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
ES2847973T3
(es)
|
2016-12-20 |
2021-08-04 |
Hoffmann La Roche |
Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
|
|
EP3559666A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Assay for determining antibody or ligand binding and function
|
|
KR102293106B1
(ko)
|
2016-12-21 |
2021-08-24 |
에프. 호프만-라 로슈 아게 |
항체의 시험관 내 당조작 방법
|
|
JP6850351B2
(ja)
|
2016-12-21 |
2021-03-31 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体のインビトロ糖鎖工学
|
|
EP3559250A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
WO2018175788A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
KR20190133162A
(ko)
|
2017-03-28 |
2019-12-02 |
제넨테크, 인크. |
신경퇴행성 질병의 치료 방법
|
|
CA3058342A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
|
|
WO2018182422A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
|
BR112019018767A2
(pt)
|
2017-04-03 |
2020-05-05 |
Hoffmann La Roche |
anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
|
|
EP4112644A1
(en)
|
2017-04-05 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Anti-lag3 antibodies
|
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EA201992522A1
(ru)
|
2017-05-17 |
2020-04-22 |
Мерус Н.В. |
КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
KR20200014304A
(ko)
|
2017-06-02 |
2020-02-10 |
에프. 호프만-라 로슈 아게 |
암의 치료를 위한 제ii형 항-cd20 항체 및 항-cd20/항-cd3 이중특이적 항체
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
US20200223924A1
(en)
|
2017-06-27 |
2020-07-16 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
JP7122370B2
(ja)
|
2017-07-26 |
2022-08-19 |
フォーティ セブン， インコーポレイテッド |
抗ｓｉｒｐ－アルファ抗体及び関連方法
|
|
EP3665198A1
(en)
|
2017-08-09 |
2020-06-17 |
Merus N.V. |
Antibodies that bind egfr and cmet
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
MX2020003497A
(es)
|
2017-10-20 |
2020-07-22 |
Hoffmann La Roche |
Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
WO2019086362A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
CN111295392A
(zh)
|
2017-11-01 |
2020-06-16 |
豪夫迈·罗氏有限公司 |
Compbody–多价靶结合物
|
|
KR102559706B1
(ko)
|
2017-11-01 |
2023-07-25 |
에프. 호프만-라 로슈 아게 |
Trifab-콘톨스바디
|
|
KR20200084006A
(ko)
|
2017-11-01 |
2020-07-09 |
에프. 호프만-라 로슈 아게 |
표적화된 ox40 작용제를 사용하는 병용 요법
|
|
BR112020008888A2
(pt)
|
2017-11-16 |
2020-10-20 |
Novartis Ag |
terapias de combinação
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3717008A1
(en)
|
2017-12-01 |
2020-10-07 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
MX2020006155A
(es)
|
2017-12-12 |
2020-08-13 |
Macrogenics Inc |
Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
|
|
SG11202005632SA
(en)
|
2017-12-21 |
2020-07-29 |
Hoffmann La Roche |
Antibodies binding to hla-a2/wt1
|
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
|
WO2019133512A1
(en)
|
2017-12-29 |
2019-07-04 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
JP7268038B2
(ja)
|
2018-01-31 |
2023-05-02 |
アレクトル エルエルシー |
抗ｍｓ４ａ４ａ抗体及びその使用方法
|
|
CN111630063A
(zh)
|
2018-01-31 |
2020-09-04 |
豪夫迈·罗氏有限公司 |
稳定化的免疫球蛋白结构域
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
US11787857B2
(en)
|
2018-02-02 |
2023-10-17 |
Bio-Techne Corporation |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
SG11202007572VA
(en)
|
2018-02-15 |
2020-09-29 |
Macrogenics Inc |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
|
JP7159332B2
(ja)
|
2018-03-13 |
2022-10-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
４－１ｂｂアゴニストと抗ｃｄ２０抗体の治療的組み合わせ
|
|
WO2019175125A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
JP2021518343A
(ja)
|
2018-03-15 |
2021-08-02 |
中外製薬株式会社 |
ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019219721A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Targeted intracellular delivery of large nucleic acids
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
MX2020011828A
(es)
|
2018-05-25 |
2021-02-09 |
Alector Llc |
Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
|
KR20210035173A
(ko)
|
2018-06-19 |
2021-03-31 |
아타르가, 엘엘씨 |
보체 성분 5에 대한 항체분자 및 이의 용도
|
|
CA3099176A1
(en)
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
|
DE202019005887U1
(de)
|
2018-07-03 |
2023-06-14 |
Marengo Therapeutics, Inc. |
Anti-TCR-Antikörpermoleküle und Verwendungen davon
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CN111372655A
(zh)
|
2018-07-13 |
2020-07-03 |
艾利妥 |
抗分拣蛋白抗体及其使用方法
|
|
JP7072715B2
(ja)
|
2018-07-20 |
2022-05-20 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ１１２ｒ組成物及び方法
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
MA50586A
(fr)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal
|
|
AU2019318031A1
(en)
|
2018-08-10 |
2021-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CD137 antigen-binding molecule and utilization thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
TW202037381A
(zh)
|
2018-10-24 |
2020-10-16 |
瑞士商赫孚孟拉羅股份公司 |
綴合化學降解誘導劑及使用方法
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
MA54525A
(fr)
|
2018-12-20 |
2021-10-27 |
Merus Nv |
Anticorps bispécifiques clec12axcd3 et méthodes de traitement d'une maladie
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019400980A1
(en)
|
2018-12-20 |
2021-06-24 |
Novartis Ag |
Pharmaceutical combinations
|
|
KR102652720B1
(ko)
|
2018-12-21 |
2024-03-29 |
에프. 호프만-라 로슈 아게 |
Vegf 및 il-1베타에 결합하는 항체 및 이의 사용 방법
|
|
AU2019410075B2
(en)
|
2018-12-21 |
2022-08-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
MX2021009769A
(es)
|
2019-02-14 |
2021-09-08 |
Merus Nv |
Produccion de composiciones que comprenden dos o mas anticuerpos.
|
|
US20220127376A1
(en)
|
2019-02-14 |
2022-04-28 |
Merus N.V. |
Combinations of binding moieties that bind egfr, her2 and her3
|
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN113329792A
(zh)
|
2019-02-15 |
2021-08-31 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス，インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
SG11202109424RA
(en)
|
2019-03-14 |
2021-09-29 |
Genentech Inc |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
TW202039578A
(zh)
|
2019-03-29 |
2020-11-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
|
TW202102261A
(zh)
|
2019-03-29 |
2021-01-16 |
美商艾特加有限責任公司 |
Fgf23之抗體分子及其用途
|
|
JP2022529154A
(ja)
|
2019-04-19 |
2022-06-17 |
ジェネンテック， インコーポレイテッド |
抗ｍｅｒｔｋ抗体及びその使用方法
|
|
CN114702587A
(zh)
|
2019-05-09 |
2022-07-05 |
美勒斯公司 |
用于使蛋白质多聚化的变体结构域及其分离
|
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
|
AU2020291300A1
(en)
|
2019-06-10 |
2022-01-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-T cell antigen-binding molecule to be used in combination with cytokine inhibitor
|
|
TW202112817A
(zh)
|
2019-06-11 |
2021-04-01 |
美商阿列克特有限責任公司 |
抗揀選蛋白抗體之使用方法
|
|
EP3990646A1
(en)
|
2019-06-26 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Mammalian cell lines with sirt-1 gene knockout
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
EP4003519A2
(en)
|
2019-07-31 |
2022-06-01 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
JP2022545457A
(ja)
|
2019-08-19 |
2022-10-27 |
メルス ナムローゼ フェンノートシャップ |
Ｌｇｒ５及びｅｇｆｒに結合する抗体とトポイソメラーゼｉ阻害剤との組合せを用いる癌の治療
|
|
AU2020345913A1
(en)
|
2019-09-12 |
2022-02-24 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
CR20220156A
(es)
|
2019-09-18 |
2022-05-23 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
|
|
AU2020348393A1
(en)
|
2019-09-20 |
2022-02-24 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing Genscript Biotech Co Ltd |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
|
BR112022007216A2
(pt)
|
2019-10-18 |
2022-08-23 |
Genentech Inc |
Métodos para tratamento de linfoma difuso, kit e imunoconjugado
|
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
IL293310A
(en)
|
2019-12-18 |
2022-07-01 |
Hoffmann La Roche |
Bispecific anti-ccl2 antibodies
|
|
WO2021122875A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/mage-a4
|
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
KR102426802B1
(ko)
*
|
2019-12-23 |
2022-07-28 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물
|
|
KR20220118527A
(ko)
|
2019-12-23 |
2022-08-25 |
제넨테크, 인크. |
아포지질단백질 l1-특이적 항체 및 이용 방법
|
|
BR112022011723A2
(pt)
|
2019-12-27 |
2022-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4 e uso do mesmo
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics Inc |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
|
BR112022013888A2
(pt)
|
2020-01-15 |
2022-09-13 |
Hoffmann La Roche |
Métodos para reduzir a quantidade de impurezas não agregadas relacionadas ao produto (napris), produzir uma solução tamponada de anticorpos monoclonais (mabs) e produzir um mab, uso de um filtro de profundidade sintético e solução tamponada de anticorpos monoclonais
|
|
CN114980902A
(zh)
|
2020-01-17 |
2022-08-30 |
诺华股份有限公司 |
用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
KR20220133196A
(ko)
|
2020-01-29 |
2022-10-04 |
메뤼스 엔.페. |
면역 세포 관여 효과를 조절하기 위한 수단 및 방법
|
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
WO2021183849A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
CN115279408A
(zh)
|
2020-03-19 |
2022-11-01 |
基因泰克公司 |
同种型选择性抗TGF-β抗体及使用方法
|
|
AU2021242249A1
(en)
|
2020-03-24 |
2022-08-18 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
|
JP2023520414A
(ja)
|
2020-03-30 |
2023-05-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2021215926A1
(en)
|
2020-04-24 |
2021-10-28 |
Merus N.V. |
Treatment of cancers with an antibody that binds lgr5 and egfr
|
|
CA3175530A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁（苏州）生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
|
JP2023526282A
(ja)
|
2020-05-13 |
2023-06-21 |
ボナム セラピューティクス，インク． |
タンパク質複合体の組成物及びその使用方法
|
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ． ホフマン－ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
|
TW202216767A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與ＣＤ３及ＦｏｌＲ１結合之抗體
|
|
AR122658A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
|
IL298402A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies that bind to CD3 and CD19
|
|
MX2022015764A
(es)
|
2020-06-19 |
2023-01-19 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis.
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
WO2022010798A1
(en)
|
2020-07-06 |
2022-01-13 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ． ホフマン－ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
|
EP4178530A1
(en)
|
2020-07-09 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Concentrated compositions of proteins, their preparation and use thereof
|
|
AU2021308712A1
(en)
|
2020-07-16 |
2023-02-02 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022016037A1
(en)
|
2020-07-17 |
2022-01-20 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
|
JP2023535409A
(ja)
|
2020-07-21 |
2023-08-17 |
ジェネンテック， インコーポレイテッド |
Ｂｒｍ分解の抗体コンジュゲート化化学的誘導物質及びｂｒｍ分解の方法
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022047046A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
JP2023542080A
(ja)
|
2020-08-26 |
2023-10-05 |
マレンゴ・セラピューティクス，インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
|
KR20230074144A
(ko)
|
2020-08-26 |
2023-05-26 |
마렝고 테라퓨틱스, 인크. |
NKp30에 결합하는 항체 분자 및 이의 용도
|
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
AU2021335509A1
(en)
|
2020-09-04 |
2023-03-09 |
F. Hoffmann-La Roche Ag |
Antibody that binds to VEGF-A and ANG2 and methods of use
|
|
EP4214244A1
(en)
|
2020-09-21 |
2023-07-26 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
MX2023003328A
(es)
|
2020-09-24 |
2023-03-27 |
Hoffmann La Roche |
Lineas de celulas de mamifero con desactivacion genica.
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combined treatments with cells expressing chimeric antigens (vehicle)
|
|
US20240002483A1
(en)
|
2020-11-16 |
2024-01-04 |
Hoffmann-La Roche Inc. |
Fab high mannose glycoforms
|
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
WO2022120352A1
(en)
|
2020-12-02 |
2022-06-09 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
|
EP4263604A1
(en)
|
2020-12-15 |
2023-10-25 |
Merus N.V. |
Treatment of cancers with an antibody that binds lgr5 and egfr
|
|
WO2022129120A1
(en)
|
2020-12-17 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
|
MX2023007309A
(es)
|
2020-12-18 |
2023-08-14 |
Merus Nv |
Composicion de anticuerpos.
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス， インコーポレイテッド |
結合剤およびそれを使用する方法
|
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
|
JP2024511970A
(ja)
|
2021-03-15 |
2024-03-18 |
ジェネンテック， インコーポレイテッド |
ループス腎炎の治療の組成物及び方法
|
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
|
|
IL307168A
(en)
|
2021-03-26 |
2023-11-01 |
Janssen Biotech Inc |
Humanized antibodies against paired helical strands of TAU protein and their uses
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117597359A
(zh)
|
2021-04-08 |
2024-02-23 |
马伦戈治疗公司 |
与tcr结合的多功能分子及其用途
|
|
EP4320444A1
(en)
|
2021-04-09 |
2024-02-14 |
F. Hoffmann-La Roche AG |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
|
KR20230160389A
(ko)
|
2021-04-22 |
2023-11-23 |
광동 파폰 바이오파마 인크. |
이중 특이성 다기능 융합 폴리펩티드
|
|
EP4326768A1
(en)
|
2021-04-23 |
2024-02-28 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
CN117396232A
(zh)
|
2021-05-12 |
2024-01-12 |
基因泰克公司 |
使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
TW202313972A
(zh)
|
2021-06-03 |
2023-04-01 |
荷蘭商美勒斯公司 |
新ｎｒｇ１融合物、融合接合處及檢測彼等之方法
|
|
JP2024520261A
(ja)
|
2021-06-04 |
2024-05-24 |
中外製薬株式会社 |
抗ｄｄｒ２抗体およびその使用
|
|
AU2022289684A1
(en)
|
2021-06-09 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
WO2022270611A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
WO2022270612A1
(ja)
|
2021-06-25 |
2022-12-29 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体の使用
|
|
KR20240032930A
(ko)
|
2021-07-13 |
2024-03-12 |
제넨테크, 인크. |
사이토카인 방출 증후군을 예측하기 위한 다변량 모델
|
|
CN117730102A
(zh)
|
2021-07-22 |
2024-03-19 |
豪夫迈·罗氏有限公司 |
异二聚体Fc结构域抗体
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
CN117897409A
(zh)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
抗类胰蛋白酶抗体的给药
|
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
IL311548A
(en)
|
2021-10-06 |
2024-05-01 |
Merus Nv |
Treatment of cancer treated with an immune checkpoint inhibitor and with high EGFR expression by an antibody that binds at least EGFR
|
|
WO2023058705A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
抗ｈｌａ－ｄｑ２．５抗体の製剤
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
|
WO2023170291A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
TW202345899A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(三)
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ｌｙ６Ｅ抗體、免疫結合物及其用途
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|